Skip to main content

Vivo Capital — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

165
Companies
$12.4B
Total invested
$110.3M
Avg. check
15
Industries
Biotechnology 20Health Care 15Therapeutics 13Pharmaceutical 9Medical 9Biopharma 7+9 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 165
Pasithea Therapeutics
November 2025

Pasithea Therapeutics is a biotechnology company that seeks to solve clinical problems such as mental health.

Biotechnology · Miami Beach$60.0M Post-IPO Equity
35Pharma
November 2024

35Pharma is a biopharmaceutical company that designs and develops innovative biologics for diseases of high unmet medical need.

Biopharma · Montreal$53.0M Series C
Timber Pharmaceuticals
January 2022

Timber Pharmaceuticals is a privately held biopharmaceutical company.

Biotechnology · Woodcliff LakeVenture - Series Unknown
Biohaven Pharmaceutical
November 2025

Biohaven is a biopharmaceutical company that develops drug candidates targeting neurological diseases.

Biotechnology · New Haven$200.0M Post-IPO Equity
Kinaset Therapeutics
January 2026

Kinaset Therapeutics is a biopharma company that focuses on advancement of novel drugs in areas of unmet medical needs.

Health Care · Boston$103.0M Series B
Cidara Therapeutics
October 2025

Cidara Therapeutics develops targeted immunotherapies aimed at improving treatment outcomes for patients with serious diseases.

Biotechnology · San Diego$339.0M Grant
Harmony Biosciences
October 2024

Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.

Biopharma · Plymouth Meeting$248.0M Post-IPO Secondary
Tricida
October 2022

Tricida operates in the healthcare industry focusing on pharmaceutical business.

Health Care · Menlo Park$125.0M Post-IPO Debt
HistoWiz
October 2021

HistoWiz provides automated histopathology for biomedical researchers.

Artificial Intelligence (AI) · Brooklyn$32.3M Series A
VectivBio
October 2022

VectivBio is a biotechnology company committed to making innovative treatments for patients suffering from serious rare diseases.

Biotechnology · Basel$125.0M Post-IPO Equity
SAB Biotherapeutics
March 2026

SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.

Biotechnology · Sioux Falls$85.0M Post Ipo Equity
Alto Neuroscience
March 2026

Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.

Artificial Intelligence (AI) · Los Altos$120.0M Post Ipo Equity
Candid Therapeutics
March 2026

Candid Therapeutics is a biotechnology company that focuses on the treatment of a range of immunological conditions.

Biotechnology · San Diego$505.0M Undisclosed
Immunic Therapeutics
February 2026

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Biotechnology · New York$400.0M Post Ipo Equity
Coherus Biosciences
February 2026

Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.

Biotechnology · Redwood City$50.1M Post Ipo Equity
Gyala Therapeutics
February 2026

Gyala Therapeutics is focused on developing new CAR-T therapies for treating hematological malignancies.

Biotechnology · BarcelonaGrant
Clene Nanomedicine
January 2026

Clene Nanomedicine focuses on the development of unique therapeutics for neurodegenerative diseases.

Biotechnology · Salt Lake City$28.0M Post Ipo Equity
EpiBiologics
January 2026

EpiBiologics develops antibody-based targeted therapies against membrane and extracellular proteins.

Biotechnology · San Mateo$107.0M Series B
CAMP4 Therapeutics
December 2025

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

Biopharma · Cambridge$30.0M Post Ipo Equity
BlossomHill Therapeutics
December 2025

BlossomHill Therapeutics is a biopharmaceutical company focusing on oncology and autoimmune disorders.

Biopharma · San Diego$84.0M Series B
Sanegene Bio
December 2025

Sanegene Bio develops an RNAi drug discovery platform designed for unmet clinical needs.

Biopharma · Woburn$110.0M Series B
Zenas BioPharma
October 2025

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Biopharma · Waltham$120.0M Post Ipo Equity
IO Biotech
September 2025

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

Biotechnology · Copenhagen$6.6M Post Ipo Equity
Semnur Pharmaceuticals
September 2025

Semnur Pharmaceuticals is a specialty pharmaceutical company focusing on clinical and commercial development of innovative products.

Biotechnology · Los Altos$100.0M Post Ipo Equity

Where Vivo Capital invests

Biotechnology20
Health Care15
Therapeutics13
Pharmaceutical9
Medical9
Biopharma7

About Vivo Capital's portfolio

How many companies has Vivo Capital invested in?

Vivo Capital has invested in 165 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Vivo Capital invest in?

Vivo Capital's top investment sectors include Biotechnology, Health Care, Therapeutics, Pharmaceutical, Medical. The firm invests across 15 different industry categories.

What is Vivo Capital's largest investment?

Among tracked funding rounds, Candid Therapeutics received $505.0M in a Undisclosed round. Vivo Capital's total known invested capital is $12.4B.

What is the average investment size for Vivo Capital?

Vivo Capital's average investment size is $110.3M across its portfolio of 165 companies.

What are Vivo Capital's most recent investments?

Recent Vivo Capital portfolio additions include Pasithea Therapeutics, 35Pharma, Timber Pharmaceuticals, Biohaven Pharmaceutical, Kinaset Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 165 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →